title: How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
abstract: Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya(®)) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.
authors: Department of Neurology, Medical University of Graz Graz, Austria.
authors: Franz
authors: F
authors: Fazekas
authors: Ovidiu
authors: O
authors: Bajenaru
authors: Thomas
authors: T
authors: Berger
authors: Tanja Hojs
authors: TH
authors: Fabjan
authors: Alenka Horvat
authors: AH
authors: Ledinek
authors: Gábor
authors: G
authors: Jakab
authors: Samuel
authors: S
authors: Komoly
authors: Tetiana
authors: T
authors: Kobys
authors: Jörg
authors: J
authors: Kraus
authors: Egon
authors: E
authors: Kurča
authors: Theodoros
authors: T
authors: Kyriakides
authors: L'ubomír
authors: L
authors: Lisý
authors: Ivan
authors: I
authors: Milanov
authors: Tetyana
authors: T
authors: Nehrych
authors: Sergii
authors: S
authors: Moskovko
authors: Panayiotis
authors: P
authors: Panayiotou
authors: Saša Šega
authors: SŠ
authors: Jazbec
authors: Larysa
authors: L
authors: Sokolova
authors: Radomír
authors: R
authors: Taláb
authors: Latchezar
authors: L
authors: Traykov
authors: Peter
authors: P
authors: Turčáni
authors: Karl
authors: K
authors: Vass
authors: Norbert
authors: N
authors: Vella
authors: Nataliya
authors: N
authors: Voloshyná
authors: Eva
authors: E
authors: Havrdová
keywords: algorithm; expert opinion; fingolimod; multiple sclerosis; treatment
references: Clin Immunol. 2010 Oct;137(1):15-20
references: 20599429
references: Lancet Neurol. 2012 May;11(5):420-8
references: 22494956
references: J Pharmacol Exp Ther. 2007 Nov;323(2):469-75
references: 17682127
references: Immunity. 2008 Jan;28(1):122-33
references: 18164221
references: Nat Rev Neurol. 2010 Jul;6(7):373-82
references: 20551946
references: Pharmacol Ther. 2007 Jul;115(1):84-105
references: 17561264
references: Mult Scler. 2012 May;18(5):662-8
references: 21965424
references: Eur J Neurol. 2011 Aug;18(8):1036-45
references: 21199183
references: N Engl J Med. 2012 May 17;366(20):1870-80
references: 22591293
references: Neurology. 2010 Aug 3;75(5):403-10
references: 20592255
references: Neurology. 2008 Oct 14;71(16):1261-7
references: 18852441
references: N Engl J Med. 2010 Feb 4;362(5):387-401
references: 20089952
references: Ann Neurol. 2011 Feb;69(2):408-13
references: 21387383
references: Br J Pharmacol. 2009 Nov;158(5):1173-82
references: 19814729
references: J Neurol. 2015 Dec;262(12):2627-34
references: 26338810
references: Wien Med Wochenschr. 2012 Aug;162(15-16):354-66
references: 22895849
references: Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101
references: 20061941
references: Discov Med. 2011 Sep;12(64):213-28
references: 21955849
references: N Engl J Med. 2010 Feb 4;362(5):402-15
references: 20089954
references: Neurology. 2011 May 31;76(22):1858-65
references: 21543733
references: Nat Rev Mol Cell Biol. 2003 May;4(5):397-407
references: 12728273
references: Nat Rev Immunol. 2008 Oct;8(10):753-63
references: 18787560